Form 4: Cytek Biosciences Executive Valerie Barnett Reports Stock Transactions
SEC Form 4 Filing
Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 11, 2024, Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reported transactions involving Cytek Biosciences common stock.
- Barnett acquired 4,908 shares of common stock through the vesting of restricted stock units (RSUs).
- She then disposed of 1,912 shares to satisfy tax withholding obligations at a price of $7.22 per share.
- Following these transactions, Barnett directly owns 36,169 shares of Cytek Biosciences common stock and 44,182 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of stock transactions (RSU vesting and tax withholding). |
| 03/13/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.